Aeolus Pharmaceuticals Announces NIH Counteract Grant Award to Develop AEOL 10150 as a Treatment Against Nerve Agent Exposure

Aeolus Pharmaceuticals, Inc. AOLS, today announced that NIH CounterACT has awarded a $735,951 contract to Manisha Patel, PhD at the University of Colorado Anschutz Medical Campus to develop AEOL 10150 as a medical countermeasure against nerve agents, titled "Evaluation of Neuroprotective Effects of AEOL 10150 against Chemical Threat Agents."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!